Focus: Coherus Oncology is a biotechnology company focused on oncology and biosimilars, headquartered in Redwood City, CA. The company operates a diversified pipeline spanning early-stage immuno-oncology programs and late-stage biosimilar development.
Profile data last refreshed 10h ago · AI intelligence enriched 2mo ago
Cooling — net -5 jobs in 30d
3 added, 8 removed. Slower than typical.
Coherus Oncology offers portfolio depth and commercial upside potential, but lacks revenue foundation and faces investor confidence challenges; best suited for risk-tolerant early-stage professionals betting on mid-2026 clinical readouts.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Coherus Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Coherus Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development - Seeking Alpha
Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development Seeking Alpha
ETFs Investing in Coherus Oncology, Inc. Stocks - TradingView
ETFs Investing in Coherus Oncology, Inc. Stocks TradingView
Coherus Oncology (NASDAQ: CHRS) posts Q2 2026 loss amid growing LOQTORZI revenue - Stock Titan
Coherus Oncology (NASDAQ: CHRS) posts Q2 2026 loss amid growing LOQTORZI revenue Stock Titan
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates Yahoo Finance
Coherus Oncology: Q2 Earnings Snapshot - AOL.com
Coherus Oncology: Q2 Earnings Snapshot AOL.com
Coherus and Zumutor Biologics Announce Clinical - globenewswire.com
Coherus and Zumutor Biologics Announce Clinical globenewswire.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo